Scott Merz

Apr 25, 2024 | pharmaceuticalonline.com | Mark Witcher |Scott Merz |Asahi Kasei Bioprocess |Joe Leuser

In bio/pharma, agile manufacturing is achieved through multipurpose designs that support a variety of unit operations manipulated and operated as independent yet connected modules. Constraints And Solutions For Biopharmaceutical ManufacturingDissect the reasons for capacity bottlenecks stemming from process development scope, downstream chromatography, and equipment constraints, and delve into the potential solutions associated with each.

Feb 6, 2024 | bioprocessonline.com | Scott Merz

Article | February 6, 2024 By Scott Merz, Sales Manager – The Americas Biopharmaceutical manufacturing is facing capacity bottlenecks due to process development, downstream chromatography, and equipment constraints. Delays in process development can lead to market competition, resource burdens, and outdated technology.